Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

1.

The practical synthesis of a novel and highly potent analogue of bryostatin.

Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacôte E, Lippa B, Nell PG, Turner TM.

J Am Chem Soc. 2002 Nov 20;124(46):13648-9.

PMID:
12431074
[PubMed - indexed for MEDLINE]
2.

The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.

Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM.

Cancer Res. 1996 May 1;56(9):2105-11.

PMID:
8616857
[PubMed - indexed for MEDLINE]
Free Article
3.

The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.

Wender PA, Hinkle KW, Koehler MF, Lippa B.

Med Res Rev. 1999 Sep;19(5):388-407. Review.

PMID:
10502742
[PubMed - indexed for MEDLINE]
4.

Biological activity of 26-succinylbryostatin 1.

Bignami GS, Wagner F, Grothaus PG, Rustagi P, Davis DE, Kraft AS.

Biochim Biophys Acta. 1996 Jul 24;1312(3):197-206.

PMID:
8703988
[PubMed - indexed for MEDLINE]
5.

Bryostatin-1: a novel PKC inhibitor in clinical development.

Kortmansky J, Schwartz GK.

Cancer Invest. 2003;21(6):924-36. Review.

PMID:
14735696
[PubMed - indexed for MEDLINE]
6.

Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.

Scala S, Dickstein B, Regis J, Szallasi Z, Blumberg PM, Bates SE.

Clin Cancer Res. 1995 Dec;1(12):1581-7.

PMID:
9815959
[PubMed - indexed for MEDLINE]
Free Article
7.

A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.

Nakagawa Y, Yanagita RC, Hamada N, Murakami A, Takahashi H, Saito N, Nagai H, Irie K.

J Am Chem Soc. 2009 Jun 10;131(22):7573-9. doi: 10.1021/ja808447r.

PMID:
19449873
[PubMed - indexed for MEDLINE]
8.

Chemistry and clinical biology of the bryostatins.

Mutter R, Wills M.

Bioorg Med Chem. 2000 Aug;8(8):1841-60. Review.

PMID:
11003129
[PubMed - indexed for MEDLINE]
9.

The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.

Hood KA, Bäckström BT, West LM, Northcote PT, Berridge MV, Miller JH.

Anticancer Drug Des. 2001 Apr-Jun;16(2-3):155-66.

PMID:
11962513
[PubMed - indexed for MEDLINE]
10.

Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP.

Baryza JL, Brenner SE, Craske ML, Meyer T, Wender PA.

Chem Biol. 2004 Sep;11(9):1261-7.

PMID:
15380186
[PubMed - indexed for MEDLINE]
Free Article
11.

Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells.

Correale P, Caraglia M, Fabbrocini A, Guarrasi R, Pepe S, Patella V, Marone G, Pinto A, Bianco AR, Tagliaferri P.

Anticancer Drugs. 1995 Apr;6(2):285-90.

PMID:
7540894
[PubMed - indexed for MEDLINE]
12.

In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

Berkow RL, Schlabach L, Dodson R, Benjamin WH Jr, Pettit GR, Rustagi P, Kraft AS.

Cancer Res. 1993 Jun 15;53(12):2810-5.

PMID:
8504423
[PubMed - indexed for MEDLINE]
Free Article
13.

The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.

Wender PA, DeBrabander J, Harran PG, Jimenez JM, Koehler MF, Lippa B, Park CM, Siedenbiedel C, Pettit GR.

Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6624-9.

PMID:
9618462
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.

Bear HD, McFadden AW, Kostuchenko PJ, Lipshy KA, Hamad GG, Turner AJ, Roberts JD, Carr M, Carr S, Grant S.

Anticancer Drugs. 1996 May;7(3):299-306.

PMID:
8792004
[PubMed - indexed for MEDLINE]
15.

Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.

Wang S, Wang Z, Dent P, Grant S.

Blood. 2003 May 1;101(9):3648-57. Epub 2003 Jan 9.

PMID:
12522001
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism.

De Lorenzo MS, Yamaguchi K, Subbaramaiah K, Dannenberg AJ.

Clin Cancer Res. 2003 Oct 15;9(13):5036-43.

PMID:
14581379
[PubMed - indexed for MEDLINE]
Free Article
18.

The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro.

Gebbia V, Citarrella P, Miserendino V, Valenza R, Borsellino N, Pesta A, Pettit R, May S.

Tumori. 1992 Jun 30;78(3):167-71.

PMID:
1440938
[PubMed - indexed for MEDLINE]
19.

Synthesis of a simplified bryostatin C-ring analogue that binds to the CRD2 of human PKC-alpha and construction of a novel BC-analogue by an unusual Julia olefination process.

Hale KJ, Frigerio M, Manaviazar S, Hummersone MG, Fillingham IJ, Barsukov IG, Damblon CF, Gescher A, Roberts GC.

Org Lett. 2003 Feb 20;5(4):499-502.

PMID:
12583753
[PubMed - indexed for MEDLINE]
20.

Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.

Elgie AW, Sargent JM, Alton P, Peters GJ, Noordhuis P, Williamson CJ, Taylor CG.

Leuk Res. 1998 Apr;22(4):373-8.

PMID:
9669842
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk